Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
The company has posted net profit of Rs. 82.62 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 77.60 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 84.29 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 118.01 crores for the Financial Year ended March 31, 2025
Tolvaptan Tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Scores highest PAT of Rs. 118 crore in FY25
The company has posted net profit of Rs. 338.55 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 1,767.63 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 55.36 crores for the Financial Year ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
